Herborium Group Developing U.K. Co-Marketing Campaign
January 13 2011 - 10:10AM
Marketwired
Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a
Botanical Therapeutics™ company, today announced the development of
a co-marketing campaign with its largest distributor, Mankind
Direct, LTD., to increase sales and market share of AcnEase®
(www.acnease.com), Herborium's proprietary, botanically based acne
and rosacea treatment, in the United Kingdom (U.K.).
To date in the U.K., Herborium has recorded AcnEase sales of
over $1M dollars, with Mankind responsible for over 50% of those
sales. A leading direct marketing provider of upscale personal care
products, Mankind is establishing a retail presence in a number of
high-end British stores. Herborium has an upcoming editorial in the
National Association of Primary Care Review read by nearly 40,000
U.K. general practitioners and dermatologists. The co-marketing
will involve joint advertising, public relations and viral and
social marketing campaigns.
"We are truly excited about increasing sales of AcnEase in the
U.K.'s robust acne and rosacea market, which is expected to grow
12.8% in 2011. The projected world market for systemic acne
products is $2.7 Billion," commented Dr. Agnes P. Olszewski,
Herborium Group's President and CEO.
Herborium's margin in the U.K. and European Union (E.U.) is very
advantageous due to growing demand for natural medicines and the
favorable currency exchange rate.
"While we expect this marketing effort to bring an additional
$500,000 in revenues, it is also advances execution of our
'Road-to-Market' Strategy calling for revenue projections of $7.5
Million, with a goal to capture 1% of the global natural and
alternative treatments market," Olszewski concluded.
About Herborium Group, Inc. Herborium
Group, Inc., a Botanical Therapeutics® company, develops, licenses
and markets proprietary, botanical based medicines to consumers and
healthcare professionals. The Company uses clinical validation to
establish and maintain a differential advantage. For more
information, please visit www.herborium.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or
alter forward-looking statements as the result of new information
or future events. We urge investors to review the risks contained
within our filings with the OTC Markets.
Investor & Media Relations: Steve Haag (832)
577-2380
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From May 2024 to Jun 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2023 to Jun 2024